Ocular Therapeutix
OCUL
65 hedge funds and large institutions have $140M invested in Ocular Therapeutix in 2018 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 25 increasing their positions, 12 reducing their positions, and 11 closing their positions.
133% more capital invested
Capital invested by funds: $60.1M → $140M (+$80.1M)
108% more repeat investments, than reductions
Existing positions increased: 25 | Existing positions reduced: 12
108% more call options, than puts
Call options by funds: $1.29M | Put options by funds: $622K
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
11.92% more ownership
Funds ownership: 45.88% → 57.79% (+12%)
6% less funds holding
Funds holding: 69 → 65 (-4)
36% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 11
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SR
Summer Road
West Palm Beach,
Florida
|
+$17M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$11.7M |
| 3 |
OM
Opaleye Management
Boston,
Massachusetts
|
+$6.25M |
| 4 |
DAM
Deltec Asset Management
New York
|
+$2.09M |
| 5 |
Jennison Associates
New York
|
+$1.68M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$277K |
| 2 |
D.E. Shaw & Co
New York
|
-$267K |
| 3 |
VF
Virtu Financial
New York
|
-$241K |
| 4 |
Wells Fargo
San Francisco,
California
|
-$186K |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
-$177K |
OCUL Hedge Fund Activity: Q1 2018 in Review
65 of the 4,373 institutional investors tracked by Wall St. Rank reported a position in Ocular Therapeutix (OCUL) for Q1 2018, worth a combined $140M — up 133% from $60.1M a quarter earlier.
Sellers outnumbered buyers: 11 funds closed out of OCUL and 7 opened new positions — a net loss of 4 holders — while 12 trimmed existing stakes and 25 added.
The largest buyer was Summer Road, opening a new position worth an estimated $17M. The largest seller was Susquehanna International Group, exiting entirely with an estimated $277K sold.
- 65 institutional investors held Ocular Therapeutix (OCUL) as of Q1 2018, down from 69 in Q4 2017.
- Funds reported $140M of Ocular Therapeutix stock for Q1 2018, up 133% quarter-over-quarter.
- 7 funds opened new Ocular Therapeutix positions in Q1 2018 and 11 closed out, a net change of -4 holders.
- The largest Ocular Therapeutix buyer in Q1 2018 was Summer Road, an estimated $17M added.
- The largest Ocular Therapeutix seller in Q1 2018 was Susquehanna International Group, an estimated $277K sold.
Based on aggregated 13F filings for Q1 2018.